retatrutide type 2 diabetes trial results 2024 Summary of the highest percent weight change in completed phase and Retatrutide: A Triple Agonist Shaping

That matters because obesity in midlife is linked with higher dementia risk, likely through these same inflammatory and vascular pathways

If youre interested in diving deeper into each of the applications summarized above, look out for more blog posts from us in the coming months

Current research focuses on elucidating its pharmacokinetic properties, dose-response relationships, and potential off-target effects in animal models

A 2022 systematic review found mixed outcomes: some gastroparesis patients tolerated low-dose GLP-1 therapy without symptom exacerbation, while others experienced significant worsening

Most symptoms tended to fade over time, Wharton says